Takeoff41 launches with $4.3M to bring AI to neonatal care in hospitals Read article Forbes features TPN2.0 as the case for purpose-built clinical AI Read article TPN2.0 research named Clinical Research Forum Top 10 Finalist Read article Takeoff41 launches feasibility study at Stanford NICU Read article
From the newsroom
August 2026 News Takeoff41 highlighted in Stanford HIT Fund's Startup Spotlight Stanford's HIT Fund highlighted Takeoff41 in its Startup Spotlight, tracing the company's path from Stanford research to a pilot at Lucile Packard Children's Hospital and its first commercial customer. July 2026 News Forbes features TPN2.0 as the case for purpose-built clinical AI Forbes features Takeoff41 as its leading example of purpose-built AI in high-stakes work, opening in Stanford's NICU where the first premature infants are receiving IV nutrition planned by AI, guided by TPN2.0. March 2026 News Takeoff41 launches with $4.3M to bring AI to neonatal care in hospitals Takeoff41 raised $4.3M in combined funding to build and deploy TPN2.0. The round was co-led by Basis Set Ventures, an early-stage AI venture fund, and Focal, which focuses on health and frontier tech. The company also secured an NIH SBIR Fast Track grant. January 2026 Related Stanford TPN AI paper wins Top 10 Award via Stanford Medicine January 2026 News Takeoff41 launches feasibility study at Stanford NICU Takeoff41 initiated a clinical feasibility study (NCT07414576) at Stanford University's neonatal intensive care unit, marking the first time TPN2.0 has been deployed in a live clinical environment. The study plans to enroll 260 infants. January 2026 News Takeoff41's TPN2.0 completes FDA review The FDA determined that TPN2.0 does not meet the definition of a regulated medical device, because the system provides recommendations that clinicians can always review, adjust, or override before any prescription is finalized. September 2025 Related CTSA-affiliated researchers' AI contributes to successful neonatal feeding interventions via Stanford Medicine September 2025 News Takeoff41 secures exclusive IP license from Stanford University Takeoff41 obtained an exclusive license from Stanford University for the patent covering the core AI methods behind TPN2.0, encompassing the data-driven approach to formulating standardized TPN compositions. September 2025 News Takeoff41 advances to NIH SBIR Fast Track Phase II Following successful completion of its Phase I milestones, which included the publication of TPN2.0's core research in Nature Medicine, Takeoff41 was awarded Phase II of its NIH SBIR Fast Track grant. July 2025 Related AI streamlining TPN infant nutrition via Pharmacy Practice News April 2025 Related TPN2.0 featured on The Incubator Podcast journal club via The Incubator April 2025 Related AI model formulates life-saving nutrition for NICU infants via The Stanford Daily
